RUNX1 and acute myeloid leukemia: We chose DOCK2 expression levels (low vs. high), therapy method (chemotherapy vs. allo-HSCT), age (<60 vs. ≥60 years), WBC counts (<20×109/L vs. ≥20×109/L), FLT3-ITD (positive vs. negative) and common AML mutations (NPM1, DNMT3A, IDH1/IDH2, RUNX1, WT1, CEBPA and TP53, mutated vs.wild) to construct multivariate analysis of EFS and OS.